Why Scaling Is Difficult

Cell and gene therapy programs progress rapidly in early research phases, but when attempting to increase manufacturing scale, maintaining cell quality and managing logistics become major obstacles. Cells are highly sensitive and can be easily damaged during transfer between production lines. These issues lead to cost increases and schedule delays, pushing back the point of investment recovery.

Core Benefits Provided by Cryopreservation

Cryopreservation enables long-term storage of cells at ultra-low temperatures. This allows produced cells to be held without immediate use, enabling production volumes to be adjusted and cells to be thawed precisely when needed. It also markedly reduces quality variability, positively influencing regulatory approval processes.

Stage Connecting to Commercial Manufacturing

When cryopreservation is applied, the cell line generated in early development can be transferred directly to the commercial manufacturing stage. This enhances process reproducibility and minimizes capital investment in production facilities, representing a strategic choice. Consequently, companies have a greater chance of achieving rapid market entry while realizing economies of scale.

Implications for the Market and Investors

The cell and gene therapy market is currently expanding rapidly into a multi-billion-dollar sector, and companies that overcome scaling barriers secure a competitive advantage. Firms that adopt cryopreservation technology demonstrate production efficiency, positioning them favorably in fundraising and partnership negotiations. Therefore, this technology is likely to become a standard in the future cell and gene therapy industry.